TABLE 3.

Adverse events (AE) during the follow‐up period.

3rd line (N = 345)		Fourth line till end of follow‐up (N = 187)
Individuals with ≥1 AEs, n (%)	132 (38.3%)	Individuals with ≥1 AEs, n (%)	85 (45.5%)
Numbers of AEs reported		Numbers of AEs reported
Mean (standard deviation)	3.9 (4.1)	Mean (standard deviation)	4.1 (4.0)
Median (interquartile range)	2.0 [1.0–4.5]	Median (interquartile range)	2.0 [1.0–5.0]
Nervous system AE	123 (35.7%)	Nervous system AE	75 (40.1%)
Headache	51 (14.8%)	Headache	35 (18.7%)
Somnolence	43 (12.5%)	Asthenia	28 (15.0%)
Dizziness	38 (11.0%)	Fatigue	21 (11.2%)
Fatigue	38 (11.0%)	Somnolence	21 (11.2%)
Asthenia	24 (7.0%)	Dizziness	18 (9.6%)
Tremor	21 (6.1%)	Tremor	17 (9.1%)
Irritability	20 (5.8%)	Blurred vision	16 (8.6%)
Cognitive dysfunction	16 (4.6%)	Diplopia	13 (7.0%)
Diplopia	15 (4.3%)	Cognitive dysfunction	8 (4.3%)
Ataxia	11 (3.2%)	Irritability	8 (4.3%)
Blurred vision	9 (2.6%)	Ataxia	7 (3.7%)
Aggression	5 (1.4%)	Aggression	4 (2.1%)
Motor incoordination	2 (0.6%)	Motor incoordination	2 (1.1%)
Worsened depression/suicidal ideation	1 (0.3%)	Worsened depression/suicidal ideation	0 (0.0%)
Gastrointestinal system AE	73 (21.2%)	Gastrointestinal system AE	48 (25.7%)
Nausea	31 (9.0%)	Diarrhea	22 (11.8%)
Diarrhea	29 (8.4%)	Vomiting	21 (11.2%)
Abdominal pain	27 (7.8%)	Abdominal pain	19 (10.2%)
Anorexia	25 (7.2%)	Anorexia	16 (8.6%)
Vomiting	23 (6.7%)	Nausea	16 (8.6%)
Weight gain	13 (3.8%)	Weight gain	10 (5.3%)
Respiratory system AE	26 (7.5%)	Respiratory system AE	19 (10.2%)
Flu syndrome	19 (5.5%)	Flu syndrome	11 (5.9%)
Rhinitis	14 (4.1%)	Rhinitis	9 (4.8%)
Infection	8 (2.3%)	Infection	5 (2.7%)
Pharyngitis	3 (0.9%)	Pharyngitis	3 (1.6%)
Other AE	25 (7.2%)	Other AE	15 (8.0%)
Lab abnormalities	11 (3.2%)	Lab abnormalities	7 (3.7%)
Renal dysfunction	10 (2.9%)	Rash	6 (3.2%)
Rash	9 (2.6%)	Renal dysfunction	5 (2.7%)
Tremor, hyponatremia, and insomnia	3 (0.9%)	Hyponatremia and insomnia	2 (1.1%)